AstraZeneca and BMS Receive Award from Major Medical Association
News May 09, 2013
The ACE Philanthropic Award is presented to an industry partner who is a member of the Corporate AACE Partnership (CAP) and has made a charitable contribution to ACE in support of the betterment of endocrine care and public health.
AstraZeneca and Bristol-Myers Squibb formed the diabetes alliance and entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for Type 2 Diabetes.
“The AstraZeneca/Bristol-Myers Squibb Diabetes Alliance is honored to be recognized with the ACE Philanthropic Award,” said Shoba Ravichandran, M.D., Group Director, AstraZeneca/Bristol–Myers Squibb Diabetes Alliance. “We share the association’s mission of providing high quality care to patients and supporting clinicians, educators and scientists in their work to overcome the burdens of diabetes and other endocrine related diseases.”
Nanoparticles show great promise as diagnostic tools and drug delivery agents. But until now, most nanoparticles had to be injected into the bloodstream because they weren’t absorbed well orally. Now, researchers have modified nanoparticles to improve their uptake in the gastrointestinal tract.